56 related articles for article (PubMed ID: 10197620)
21. Advances in preclinical investigation of prostate cancer gene therapy.
Figueiredo ML; Kao C; Wu L
Mol Ther; 2007 Jun; 15(6):1053-64. PubMed ID: 17457317
[TBL] [Abstract][Full Text] [Related]
22. Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system.
Figueiredo ML; Sato M; Johnson M; Wu L
Future Oncol; 2006 Jun; 2(3):391-406. PubMed ID: 16787119
[TBL] [Abstract][Full Text] [Related]
23. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
Zhu M; Bristol JA; Xie Y; Mina M; Ji H; Forry-Schaudies S; Ennist DL
J Virol; 2005 May; 79(9):5455-65. PubMed ID: 15827160
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional Targeting in Cancer Gene Therapy.
Robson T; Hirst DG
J Biomed Biotechnol; 2003; 2003(2):110-137. PubMed ID: 12721516
[TBL] [Abstract][Full Text] [Related]
25. Intravascular adenoviral agents in cancer patients: lessons from clinical trials.
Reid T; Warren R; Kirn D
Cancer Gene Ther; 2002 Dec; 9(12):979-86. PubMed ID: 12522437
[TBL] [Abstract][Full Text] [Related]
26. Gene therapy for prostate cancer.
Gingrich JR; Chauhan RD; Steiner MS
Curr Urol Rep; 2001 Jun; 2(3):199-208. PubMed ID: 12084265
[TBL] [Abstract][Full Text] [Related]
27. Gene therapy for prostate cancer.
Gingrich JR; Chauhan RD; Steiner MS
Curr Oncol Rep; 2001 Sep; 3(5):438-47. PubMed ID: 11489246
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes.
Balagué C; Noya F; Alemany R; Chow LT; Curiel DT
J Virol; 2001 Aug; 75(16):7602-11. PubMed ID: 11462032
[TBL] [Abstract][Full Text] [Related]
29. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy.
Doronin K; Kuppuswamy M; Toth K; Tollefson AE; Krajcsi P; Krougliak V; Wold WS
J Virol; 2001 Apr; 75(7):3314-24. PubMed ID: 11238857
[TBL] [Abstract][Full Text] [Related]
30. Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway.
Brunori M; Malerba M; Kashiwazaki H; Iggo R
J Virol; 2001 Mar; 75(6):2857-65. PubMed ID: 11222711
[TBL] [Abstract][Full Text] [Related]
31. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.
Kurihara T; Brough DE; Kovesdi I; Kufe DW
J Clin Invest; 2000 Sep; 106(6):763-71. PubMed ID: 10995787
[TBL] [Abstract][Full Text] [Related]
32. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.
Yu DC; Chen Y; Seng M; Dilley J; Henderson DR
Cancer Res; 1999 Sep; 59(17):4200-3. PubMed ID: 10485454
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer.
Young CY; Seay T; Hogen K; Charlesworth MC; Roche PC; Klee GG; Tindall DJ
Prostate Suppl; 1996; 7():17-24. PubMed ID: 8950360
[TBL] [Abstract][Full Text] [Related]
34. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate.
Rittenhouse HG; Finlay JA; Mikolajczyk SD; Partin AW
Crit Rev Clin Lab Sci; 1998 Aug; 35(4):275-368. PubMed ID: 9759557
[TBL] [Abstract][Full Text] [Related]
35. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
Yu DC; Sakamoto GT; Henderson DR
Cancer Res; 1999 Apr; 59(7):1498-504. PubMed ID: 10197620
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
37. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen.
Pang S; Dannull J; Kaboo R; Xie Y; Tso CL; Michel K; deKernion JB; Belldegrun AS
Cancer Res; 1997 Feb; 57(3):495-9. PubMed ID: 9012480
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
